Remove 2019 Remove Epilepsy Remove Safety Remove Treatment
article thumbnail

GW Pharmaceuticals receives approval for EPIDYOLEX® (cannabidiol) from the MHRA for the treatment of seizures associated with tuberous sclerosis complex

Cannabis Law Report

GW was initially granted marketing authorisation for this medicine in the UK in September 2019 as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older.

article thumbnail

GW’s Cannabis-Based Epilepsy Drug Set For European Approval

Cannabis Law Report

Following an encouraging initial US launch, GW Pharmaceuticals’s cannabidiol oral solution is also set to achieve European approval later in 2019. Cannabidiol-based treatment receives marketing approval from EMA. Knowledge, attitudes and policies regarding medical cannabis and cannabis-based drugs are changing.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA Stresses CBD Safety Concerns in 15 Warning Letters and Revised Consumer Update

The Blunt Truth

In addition to the letters, the FDA published a revised Consumer Update detailing safety concerns about CBD products more broadly. The FDA also highlighted the issue it has proclaimed since May 2019, when the CBD Policy Working Group held a public hearing–“many unanswered questions and data gaps about CBD toxicity” remain.

Safety 68
article thumbnail

A New Treatment: CBD Oil For Autism?

Puff Puff Post

An official study is aimed to conclude in July of 2019, where we’ll see all the data which comes forth. The Current Treatments for Autism. Most education-based autism treatment is focused on teaching developing children self-care, communicative, and social skills. As it sits, only a few methods of treating autism are available.

article thumbnail

GW Pharmaceuticals Pre-Announces Preliminary Unaudited Fourth Quarter and Full-Year 2019 Net Product Sales

Cannabis Law Report

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. 14th at 11:00 a.m. PT (2:00 p.m.

article thumbnail

Thailand: Press Release Thailand Govt Pharma Organization “Pharmaceutical Organization, Department of Medical Cooperation, Research on Medical Marijuana Extracts For cancer patients with neurodegenerative epilepsy And nervous pain”

Cannabis Law Report

30 May 2019. The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths. Effective, most effective in treatment Relieve symptoms.

article thumbnail

Everything MMJ Patients Need To Know About Medical Marijuana Dispensaries in Texas

MMJ Recs

However, the tide began to turn in 2015 when the state legislature passed the Compassionate Use Act, allowing for the limited use of low-THC cannabis for patients with intractable epilepsy. Qualifying conditions include epilepsy, terminal cancer, multiple sclerosis, autism, and incurable neurodegenerative diseases.